Their prescribing protocol, monitoring targets, and likely co-prescriptions are different
SCS includes low-frequency SCS (frequency 10100 Hz, pulse width 1001,000 ms, and amplitude 110 mA) that applies paresthesia-based stimulation and high-frequency SCS (frequency 110 kHz, pulse width 30150 ms, and amplitude 15 mA) that applies stimulation below the paresthesia threshold [96]
Retrieved 2025-12-13
Previous strategies to overcome these barriers, including dose optimization, image-guided planning, and combination systemic therapy, have achieved only incremental gains, leaving a significant unmet clinical need for innovative, tumor-targeted solutions [18, 19]
Which conditions does the article say make the long half-life especially worth discussing
Fardi, F